Paula Pérez Terns

Paula Pérez Terns is the head of the Heart Failure Unit at Sanatorio Dupuytren, where she has contributed to advancements in understanding cardiovascular health. She has been involved in significant research regarding the effects of semaglutide, a drug originally used for diabetes management, which has shown promise in reducing cardiovascular risks beyond weight loss. Her insights are shaping how medical professionals view the treatment of cardiac conditions, particularly in patients with obesity and diabetes.